Pediapharm Inc. (CVE:MDP) – Research analysts at Cormark issued their Q2 2020 earnings per share (EPS) estimates for Pediapharm in a report issued on Wednesday, July 10th. Cormark analyst T. Gonsalves anticipates that the company will post earnings per share of ($0.15) for the quarter. Cormark also issued estimates for Pediapharm’s Q4 2020 earnings at ($0.18) EPS.
Separately, Bloom Burton reaffirmed an “accumulate” rating on shares of Pediapharm in a report on Wednesday, July 3rd.
CVE MDP opened at C$4.47 on Friday. The company has a quick ratio of 2.73, a current ratio of 3.17 and a debt-to-equity ratio of 39.02. Pediapharm has a 52-week low of C$3.80 and a 52-week high of C$7.05.
Pediapharm Company Profile
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It distributes prescription medicines that are used to treat pathological conditions, which primarily affect children from infancy to 18 years of age; and commercializes non-prescription products, such as non-prescription drugs and medical devices that fulfill unmet medical needs of children.
Recommended Story: Differences Between Momentum Investing and Long Term Investing
Receive News & Ratings for Pediapharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediapharm and related companies with MarketBeat.com's FREE daily email newsletter.